Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/08/23
End: 10/31/25
Due: 10/31/26
Phase: N/A
Priority: Normal
Start: 12/01/20
End: 07/13/22
Due: 07/13/23
Phase: N/A
Priority: Normal
Start: 10/31/24
End: 08/31/27
Due: 08/31/28
Phase: N/A
Priority: Normal
Start: 06/28/22
End: 01/13/24
Due: 01/13/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion | NCT06115512 | Angitia Biopharmaceuticals | user2@example.com | None | 2023-12-08 | 2025-10-31 | 2026-10-31 | - | - | 2025-07-14 |
| A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease | NCT05574543 | Angitia Biopharmaceuticals | user2@example.com | None | 2020-12-01 | 2022-07-13 | 2023-07-13 | - | - | 2025-07-14 |
| A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | NCT06577935 | Angitia Biopharmaceuticals | user2@example.com | None | 2024-10-31 | 2027-08-31 | 2028-08-31 | - | - | 2025-07-14 |
| A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women | NCT05225857 | Angitia Biopharmaceuticals | user2@example.com | None | 2022-06-28 | 2024-01-13 | 2025-01-13 | - | - | 2025-07-14 |